Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
Retrieved on:
Friday, December 2, 2022
Dai, Peptide, Focus X, Full Life Christian Centre, CADD, CMC, Cryogenic electron microscopy, PCC, Radiopharmaceutical, Trust, Chemical substance, IIT, Therapy, Cancer, Research, ASMS, CSO, HDX, EFS, Toxicity, DNA, Patient, Acquisition, Euler's totient function, SPR, Head, Control, CIO, Antibody, Drug, PDC, Pharmaceutical industry, Fine chemical, Manufacturing
They completed their angel round in the third quarter of 2020, which was led by Viva.
Key Points:
- They completed their angel round in the third quarter of 2020, which was led by Viva.
- In addition to financial support, Viva also provided Focus-X with comprehensive incubation services to help it realize the transformation from "concept to product."
- Viva provides efficient and high-quality screening and synthesis services for Focus-X with the help of its peptide research and development platform.
- Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators.